687631-80-7

Basic information

• Product Name: ALFA-AMINO-3-NITROBENZENEACTIC ACID METHYL ESTER
• Synonyms: ALFA-AMINO-3-NITROBENZENEACTIC ACID METHYL ESTER
• CAS NO: 687631-80-7
• Molecular Formula: C9H10N2O4
• Molecular Weight: 210.19
• Mol File: 687631-80-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 314.3±32.0 °C(Predicted)
• Appearance: /
• Density: 1.326±0.06 g/cm3(Predicted)
• PKA: 6.11±0.10(Predicted)
• CAS DataBase Reference: ALFA-AMINO-3-NITROBENZENEACTIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: ALFA-AMINO-3-NITROBENZENEACTIC ACID METHYL ESTER(687631-80-7)
• EPA Substance Registry System: ALFA-AMINO-3-NITROBENZENEACTIC ACID METHYL ESTER(687631-80-7)

Safety Data

• Hazardous Substances Data: 687631-80-7(Hazardous Substances Data)

Usage

Main Properties

1. Chemical Structure: Consists of a benzene ring with a nitro group (-NO2) and an amino group (-NH2) attached, along with a carboxylic acid group (-COOH) and a methyl ester (-COOCH3).
2. Functional Groups: Contains key functional groups such as nitro, amino, carboxylic acid, and ester.
3. Molecular Formula: Typically represented as C9H9NO5.
4. Molecular Weight: Calculated approximately as 211.17 g/mol.

Specific Content

1. Medicinal and Pharmaceutical Applications:
Building Block: Used as a foundational component in the synthesis of various drugs and pharmaceuticals.
Drug Development: Its chemical structure and properties make it valuable in developing new drugs and therapeutic compounds.
Synthetic Role: Plays a crucial role in the creation of pharmaceuticals with diverse applications.

2. Potential Uses in Chemical Synthesis:
Versatile Reactivity: Its unique structure and reactivity may find applications beyond pharmaceuticals.
Chemical Synthesis: Could be employed in other chemical synthesis processes due to its versatile nature.

3. Overall Significance:
Synthesis and Development: Plays a significant role in the synthesis and development of pharmaceuticals and other chemical compounds.
Industry Impact: Contributes to advancements in the pharmaceutical industry by facilitating the creation of new drugs and therapeutic agents.

This compound serves as a fundamental building block in pharmaceutical synthesis, owing to its diverse functional groups and reactivity, potentially impacting various aspects of drug development and chemical synthesis processes.

Upstream product

• 2835-06-5 phenylglycin 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 30077-08-8 d-α-amino-m-nitrophenylacetic acid 
• 67-56-1 methanol 

Relevant articles and documents

Ru-catalyzed C[sbnd]H functionalization of phenylglycine derivatives: Synthesis of isoquinoline-1-carboxylates and isoindoline-1-carboxylates

The reaction of N-unprotected methylesters of phenylglycine derivatives (1a–1f) with electron-rich internal alkynes (2a–2e), catalyzed by [Ru(cymene)Cl2]2 (10%), gives the corresponding 3,4-disubstituted isoquinoline-1-carboxylates 3 through C[sbnd]H/N[sbnd]H oxidative coupling. The C[sbnd]H bond activation step is assisted by carboxylates, and N-fluoro-2,4,6-trimethylpyridinium triflate works as the terminal oxidant. The process shows a remarkable tolerance to the presence of diverse electron-releasing and electron-attracting functional groups at the phenyl ring of the amino acid. In addition, the reaction of phenylglycine derivatives (1a–1f) with methyl acrylate (4a) catalyzed by [Ru(cymene)Cl2]2 (10%) under the same experimental conditions, gives the corresponding 3,N-disubstituted isoindoline-1-carboxylates 5 through C[sbnd]H/N[sbnd]H coupling. Isoindolines 5 are obtained as a mixture of diastereoisomers, with moderate to high values of diastereomeric excess (up to 80%).

GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.